Navigation Links
Statins decrease risk of clot-related diseases
Date:5/16/2010

ATS 2010, NEW ORLEANS Individuals at risk for clot-related diseases may benefit from taking common cholesterol-lowering drugs known as statins, according to a study conducted by researchers at the University of Connecticut.

The results of the study will be presented at the ATS 2010 International Conference in New Orleans.

"Previous clinical studies have indicated statins may play a role in lowering the risk of these conditions, but these studies have yielded variable estimates of the effect of statin therapy," said lead author Vanjul Agarwal, M.B.B.S. "In our study, we aimed to analyze and evaluate the effect of these drugs in patients with specific conditions related to vessel blockages."

While other studies have focused on the effects of specific statin drugs, Dr. Agarwal said the current analysis sought to evaluate the effect of statins as a whole. Researchers reviewed the results of 10 studies of more than 900,000 men and women evaluating the effect of statins in preventing venous thromboembolism (VTE), clots formed in the deep veins which pose a serious risk for heart attack and stroke. Dr. Agarwal noted that the current study included all types of VTE, with a focus on deep vein thrombosis (DVT), most commonly involving clots in the lower legs, and pulmonary embolism (PE), clots that form in the primary vessels of the lungs after migrating from other areas of the body, usually the legs, pelvis or, rarely, arms. According to study results, statin use benefited patients with all types of VTE, including DVT and PE.

Both PE and DVT can be asymptomatic and therefore difficult to detect, or easy to misdiagnose. According to the Centers for Disease Control, about 200,000 to 400,000 people in the U.S. have DVT and about 100,000 to 200,000 people have a PE. Nearly one-third of individuals with a PE die as a result of the condition.

Dr. Agarwal said statins are believed to decrease the risk of VTE by reducing inflammation, one of the factors involved in clot formation. "Statins have been found to have anti-inflammatory properties. Since thrombus formation involves inflammation, statins may reduce venous thrombus formation and thus, lower the odds of developing PE/DVT," she said.

Dr. Agarwal noted future randomized, controlled trials may help determine a course of statin therapy for patients most at risk for developing VTE.

"Patients at high risk for developing PE or DVT may be prescribed statins prophylactically," she said. "In these patients, regular use of statins could significantly reduce the incidence of PE and DVT."


'/>"/>

Contact: Keely Savoie
KSAVOIE@THORACIC.ORG
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Statins Show Promise Against Sickle Cell
2. More Evidence That Statins Cut Stroke Risk
3. Statins May Benefit Prostate Cancer Patients
4. Alternative to Statins Shows Promise
5. Statins may slow progression of multiple sclerosis, new study finds
6. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
7. Do Statins Lower Male Sex Drive?
8. Statins Wont Lower Colon Cancer Risk
9. Decreased muscle strength predicts functional impairments in older adults
10. The Pill May Decrease Bone Density
11. Severe sleep apnea decreases frequency of nightmare recall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering the many ... learn more about the options currently available to them and which ones might work ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... growth round of funding led by Eastside Partners, with participation from existing investor ... growing customer base and accelerate its technology and product roadmap. , ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions ... to Work employee satisfaction survey, earning them second place for Tampa’s Best Places to ... employees. , “This is a great accomplishment for our team,” says RMS Human ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) ... Daniel A. Potter -- are proud of the recent release of their 2014 in ... SART published the latest verified data for 375 U.S. member clinics. *Preliminary ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... 2016 Research and Markets has ... Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected ... period 2016-2020. , ,The growing adoption of laser in ... of the market. Lasers are used to treat a ...
(Date:4/28/2016)... YORK , April 28, 2016 ... online consumer insights on healthcare, announced today that it ... their report Cool Vendor in Life Sciences, 2016, ... April 15, 2016.  The report focuses on life-science- oriented ... gain insight from patients and doctors, confirm medication ingestion, ...
Breaking Medicine Technology: